MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
Open Access
- 1 August 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (3) , 1019-1027
- https://doi.org/10.1182/blood-2002-11-3507
Abstract
The mitogen-activated protein kinase (MAPK) (also called extracellular signal–regulated kinase [ERK]) pathway has been implicated in malignant transfKeywords
This publication has 53 references indexed in Scilit:
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer CellsPublished by Elsevier ,2001
- Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell linesBlood, 2001
- Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasiasExpert Opinion on Investigational Drugs, 2001
- TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2Oncogene, 2001
- MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL ReceptorsJournal of Biological Chemistry, 2001
- TRAIL Causes Cleavage of Bid by Caspase-8 and Loss of Mitochondrial Membrane Potential Resulting in Apoptosis in BJAB CellsBiochemical and Biophysical Research Communications, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed‐Sternberg cellsEuropean Journal of Immunology, 1995